Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Samsung Bioepis, C-Bridge look to China expansion
March 2019
SHARING OPTIONS:

INCHEON, Korea—Samsung Bioepis Co. Ltd. and C-Bridge Capital have signed a licensing agreement covering several of Samsung Bioepis’ biosimilar candidates, including SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, and SB3, which references Herceptin. C-Bridge will establish AffaMed Therapeutics, a new biopharmaceutical company, which will work with Samsung Bioepis in a variety of fields in China. Samsung Bioepis stands to receive an upfront payment and royalties on any sales resulting from this agreement.
 
“We want to play an important role in widening access to high-quality healthcare for patients throughout China. C-Bridge is the right partner for this mission as evidenced in its exceptional track record of successfully turning portfolio companies like AffaMed Therapeutics into leading biopharmaceutical companies in China and beyond,” commented Christopher Hansung Ko, president and CEO of Samsung Bioepis.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.